BOT - Anything but charting, page-10503

Next Steps will be covered next week and brocket will rush to update their valuation again:

Payer negotiations are ongoing with the list price originally discussed under an NDA, but BOT are moving towards publishing thisnumber to the payer compendium. The aim is for a favourable net price after accounting for managed care and patient rebates,copays, pharmacy setup, logistics etc. We assume this net price at launch will be ~$490, with an ~35% gross to net.■ Launch Preparation is underway with payer negotiations with account managers, clinician meetings, sales staff interviews underway,marketing preparation and utilisation of crossix data with partners to support target segmentation.■ The messaging for BOT's Patient Experience Program is currently being finessed to make "alpha" patients within the InternationalHyperhidrosis Society database aware of the opportunity.■ Further detail around the engagement with payers on pricing, as well as feedback on the progress on the Patient ExperienceProgram is expected at a market update in mid-August.